Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Cancer Res. 2010 Mar 23;70(7):2924–2931. doi: 10.1158/0008-5472.CAN-09-3436

Figure 4.

Figure 4

ERK1/2 activation in transgenic mice treated 9 months with exogenous estrogen. Sections from nontransgenic, E6, and E5 transgenic mice were immunohistochemically stained for the presence of phosphorylated ERK1/2. Shown are representative pictures of cervical epithelium (left panels) and tumors (right panels) from nontransgenic, E6, and E5 transgenic mice treated with exogenous estrogen for 9 months. Right panels insets: higher magnifications of epithelium. Bottom right panel: no primary antibody control.